loading
Theravance Biopharma Inc stock is traded at $11.05, with a volume of 26,952. It is down -0.18% in the last 24 hours and up +5.01% over the past month. Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$11.13
Open:
$11.09
24h Volume:
26,952
Relative Volume:
0.10
Market Cap:
$552.76M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-12.01
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
-1.24%
1M Performance:
+5.01%
6M Performance:
+6.11%
1Y Performance:
+8.81%
1-Day Range:
Value
$11.05
$11.18
1-Week Range:
Value
$11.08
$11.41
52-Week Range:
Value
$7.44
$11.88

Theravance Biopharma Inc Stock (TBPH) Company Profile

Name
Name
Theravance Biopharma Inc
Name
Phone
650-808-6000
Name
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Name
Employee
97
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
TBPH's Discussions on Twitter

Compare TBPH with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TBPH
Theravance Biopharma Inc
11.05 565.02M 62.02M -45.65M -9.60M -0.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.04 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.55 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
327.43 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.37 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.82 31.91B 3.81B -644.79M -669.77M -6.24

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-06-24 Downgrade Leerink Partners Outperform → Market Perform
Apr-12-24 Initiated BTIG Research Buy
Jan-08-24 Downgrade Evercore ISI Outperform → In-line
May-23-22 Initiated SVB Leerink Outperform
Nov-05-21 Upgrade JP Morgan Underweight → Neutral
Sep-15-21 Downgrade JP Morgan Overweight → Underweight
Aug-25-21 Downgrade Morgan Stanley Overweight → Underweight
Aug-24-21 Downgrade Cowen Outperform → Market Perform
Oct-14-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-07-20 Initiated JP Morgan Overweight
Jun-15-20 Initiated Morgan Stanley Equal-Weight
May-13-20 Initiated Cowen Outperform
Jan-08-20 Reiterated H.C. Wainwright Buy
Nov-06-19 Upgrade Robert W. Baird Underperform → Neutral
Oct-29-19 Initiated H.C. Wainwright Buy
Mar-29-18 Resumed Piper Jaffray Overweight
Aug-17-17 Initiated Evercore ISI Outperform
Jun-16-17 Initiated Cantor Fitzgerald Overweight
May-11-17 Reiterated Needham Buy
Dec-21-16 Initiated Needham Buy
Nov-03-16 Initiated Piper Jaffray Overweight
Oct-12-16 Downgrade Robert W. Baird Neutral → Underperform
Aug-03-16 Downgrade BofA/Merrill Neutral → Underperform
Jun-20-16 Initiated Guggenheim Buy
Jun-20-16 Reiterated Leerink Partners Outperform
May-12-16 Initiated Leerink Partners Outperform
May-05-16 Downgrade BofA/Merrill Buy → Neutral
Feb-03-15 Upgrade Robert W. Baird Underperform → Neutral
View All

Theravance Biopharma Inc Stock (TBPH) Latest News

pulisher
02:51 AM

Why Theravance Biopharma Inc. stock attracts strong analyst attentionWealth Accumulation Stock List - Newser

02:51 AM
pulisher
Jul 24, 2025

Is Theravance Biopharma Inc. a good long term investmentRecord-breaking gains - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

What analysts say about Theravance Biopharma Inc. stockUnbelievable profit margins - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 23, 2025

Theravance Biopharma Inc. Stock Analysis and ForecastExceptional trading results - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizen Tribune

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Theravance Biopharma Inc. stock priceConsistent triple-digit returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

How Theravance Biopharma Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser

Jul 22, 2025
pulisher
Jul 17, 2025

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail

Jul 17, 2025
pulisher
Jul 16, 2025

Theravance Biopharma SVP Farnum sells $113,869 in stock By Investing.com - Investing.com Nigeria

Jul 16, 2025
pulisher
Jul 16, 2025

Theravance Biopharma SVP Farnum sells $113,869 in stock - Investing.com

Jul 16, 2025
pulisher
Jul 16, 2025

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Theravance Biopharma Inc. stock price move sharplyStrategic High Profit Opportunities - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $16.60 - Defense World

Jul 15, 2025
pulisher
Jul 14, 2025

Theravance Biopharma SVP Sells 7,000 Shares for $78,000 on July 14, 2025. - AInvest

Jul 14, 2025
pulisher
Jul 13, 2025

Theravance higher as China approves Viatris-partnered COPD therapy - MSN

Jul 13, 2025
pulisher
Jul 12, 2025

Theravance Biopharma (NASDAQ:TBPH) Downgraded to “Hold” Rating by Wall Street Zen - Defense World

Jul 12, 2025
pulisher
Jun 30, 2025

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell 2000 Defensive Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Theravance Biopharma, Inc.(NasdaqGM: TBPH) added to Russell Microcap Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 28, 2025

Theravance Biopharma (NASDAQ:TBPH) Given New $25.00 Price Target at BTIG Research - Defense World

Jun 28, 2025
pulisher
Jun 27, 2025

TBPH Stock Price Target Increased Following Milestone Payment | TBPH Stock News - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛

Jun 27, 2025
pulisher
Jun 26, 2025

Theravance Biopharma price target raised to $25 by BTIG on China approval - Investing.com

Jun 26, 2025
pulisher
Jun 25, 2025

Is Theravance Biopharma, Inc. technically bullish or bearish? - MarketsMojo

Jun 25, 2025
pulisher
Jun 18, 2025

Theravance Biopharma (NASDAQ:TBPH) Now Covered by Jones Trading - Defense World

Jun 18, 2025
pulisher
Jun 18, 2025

Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Jones Trading - Defense World

Jun 18, 2025

Theravance Biopharma Inc Stock (TBPH) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.29
price down icon 1.74%
$36.50
price up icon 0.00%
$103.56
price down icon 0.03%
$27.38
price down icon 0.69%
$113.86
price down icon 0.68%
biotechnology ONC
$288.37
price down icon 2.39%
Cap:     |  Volume (24h):